Expression of human recombinant granzyme A zymogen and its activation by the cysteine proteinase cathepsin C.
Human granzyme A is one of the serine proteinases present in the granules of cytotoxic T lymphocytes and natural killer cells. Granzymes are synthesized as inactive proenzymes with an amino-terminal prodipeptide, which is processed during transport of granzymes to the cytotoxic granules, where they are stored as active proteinases. In this study, we explored the possibility of producing recombinant granzymes. Recombinant human granzyme A zymogen was expressed in several eukaryotic cell lines (HepG2, Jurkat, and COS-1) after infection with a recombinant vaccinia virus containing full-length granzyme A cDNA. Immunoblot analysis of cell lysates showed that all infected cells produced a disulfide-linked homodimer of identical molecular weight as natural granzyme A. Infected HepG2 cells produced the largest amount of this protease (approximately 160 times more than lymphokine activated killer (LAK) cells). The recombinant protein only had high mannose type oligosaccharides as did the natural protein. Although infected HepG2 and COS cells contained high granzyme A antigen levels, lysates from these cells did not show any granzyme A proteolytic activity. However, the inactive proenzyme could be converted into active granzyme A by incubation with the thiol proteinase cathepsin C (dipeptidyl peptidase I). This study is the first to demonstrate expression of an active recombinant human cytotoxic lymphocyte proteinase and conversion of inactive progranzyme A into an active enzyme by cathepsin C. We suggest that a similar approach can be used for the production of other granzymes and related proteinases.
Kummer
J A
JA
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, University of Amsterdam, Amsterdam, The Netherlands.
Kamp
A M
AM
Citarella
F
F
Horrevoets
A J
AJ
Hack
C E
CE
D000818:Animals; D000911:Antibodies, Monoclonal; D020789:Cathepsin C; D002460:Cell Line; D002478:Cells, Cultured; D003594:Cytoplasmic Granules / Q000201:enzymology; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000378:metabolism*; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000096:biosynthesis / Q000378:metabolism*; D053804:Granzymes; D006801:Humans; D015151:Immunoblotting; D015979:Killer Cells, Lymphokine-Activated / Q000201:enzymology; D007694:Killer Cells, Natural / Q000201:enzymology; D007700:Kinetics; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000378:metabolism; D012697:Serine Endopeptidases / Q000096:biosynthesis* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000201:enzymology; D014162:Transfection; D014407:Tumor Cells, Cultured; D014616:Vaccinia virus
D000911:Antibodies, Monoclonal; D004792:Enzyme Precursors; D011994:Recombinant Proteins; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D020789:Cathepsin C; D053804:Granzymes; D012697:Serine Endopeptidases; C509212:GZMA protein, human